Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Sharemaestro Market Watch Weekly signal
The diagnostics stock’s latest weekly move extended a sharp three-month advance, with turnover running above its recent average.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current …
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the "Insiders Fund". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% …
While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading
Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening …
Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate …
Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …
Cigna Group recently declared a US$1.56 per share cash dividend with an ex-dividend date of September 8, 2026, while Jefferies downgraded its rating to 'hold' due to anticipated 2027 earnings headwinds. This situation highlights a tension between management's commitment to returning capital to shareholders …
Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …
Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …
Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …
Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …
Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how …
Search by ticker symbol or company name and select a result to open its chart.